



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

AK

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/690,197	10/16/00	COLLINS	D COP1001

HM22/0417

SHERRY M KNOWLES
KING & SPALDING
191 PEACHTREE STREET NE
45TH FLOOR
ATLANTA GA 30303

EXAMINER

LUKTON, D

ART UNIT	PAPER NUMBER
1653	4

DATE MAILED: 04/17/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No. 09/690,197	Applicant(s) Collins
Examiner David Lukton	Art Unit 1653

-- The MAILING DATE of this communication appears on the cover sheet with the corresponding address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE one MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on Feb 12, 2001

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle* 1035 C.D. 11; 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-72 is/are pending in the application.
- 4a) Of the above, claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claims 1-72 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are objected to by the Examiner.
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

a) All b) Some* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- 15) Notice of References Cited (PTO-892)
- 16) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____
- 18) Interview Summary (PTO-413) Paper No(s). _____
- 19) Notice of Informal Patent Application (PTO-152)
- 20) Other: _____

A restriction is imposed, as set forth below. First, however, the following subgenera are defined.

G1: The claimed compound does not contain any boron.

G2: The "molecule comprising B-10" is a peptide or amino acid

G3: The "molecule comprising B-10" is a carbohydrate or nucleoside or carborane.

G4: The "molecule comprising B-10" can be whatever the claims permit, provided that G2 and G3 are excluded.

*

Restriction to one of the following inventions is required under 35 U.S.C. §121:

1. Claims 1-10, 13-37, 40-44, 49, 54-68, 72, drawn to compounds of G2, provided that G1 is excluded.
2. Claims 1-44, 49, 54-68, 72 drawn to compounds of G3, provided that G1 is excluded.
3. Claims 1-9, 13-36, 40-44, 49, 54-68, 72, drawn to compounds of G4, provided that G1 is excluded.
4. Claims 24-43, 54-68, 72, drawn to compounds which do not contain B-10.
5. Claims 69-71, drawn to a method of using the compounds of Group 1.
6. Claims 69-71, drawn to a method of using the compounds of Group 2.
7. Claims 69-71, drawn to a method of using the compounds of Group 3.

8. Claims 69-71, drawn to a method of using the compounds of Group 4.

Claims 45-48, 50-53 are not grouped. These claims are not properly dependent. For example, claim 46 makes reference to "the non-metallic radionuclide of claim 3". However, there is no non-metallic radionuclide mentioned in any of claims 1, 2 or 3. In the event that applicants amend claims 46-48, 50-53 so that their dependence is proper, these claims will be grouped appropriately. Claims 73 and 74 are also not grouped; these are drawn to a "use", which is not a proper statutory class. These will also be grouped appropriately if amended in conformance with U.S. practice.

The claimed inventions are distinct.

Subgenus G1 has been created because it is somewhat unclear as to whether boron is required in all of the claims. It appears that claims 24-43, 54-68, 72 permit, but do not require boron. If, on the other hand, all of the claims do require boron, then applicants can just disregard group 4.

Groups 1 and 2 are distinguished on basis of the "molecule comprising B-10". However, in the event that either of Groups 1 or 2 is elected, and claims found allowable, the possibility of rejoining the other (of Groups 1 and 2) is not precluded. Group 4 might also be joined with Group 1 or 2.

Inventions {1-4} and {5-8} are related as product and process of use. The inventions can

be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP 806.05(h)). However, in the event that group I is elected, and the claims found allowable, the method claims will be rejoined for further examination [*In re Ochiai* (37 USPQ2d 1127)].

Applicant is advised that for the response to this requirement to be complete, an election of the invention to be examined must be indicated, even if the requirement is traversed (37 C.F.R. 1.143).

Applicant is reminded that upon cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

In addition to the foregoing, applicants are required under 35 U.S.C. §121 to elect a disclosed specie for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. A "specie" is a specific compound, with all substituent variables fully accounted for.

Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a generic claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP 809.02(a).

Should applicant traverse on the ground that the species are not patentable distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. §103 of the other invention.

There is an error in figure 1. In the "B" ring, substituent variable "X" is shown as being double-bonded to the adjacent carbon atom. Instead, the nitrogen atom of the "B" ring should be double bonded to the adjacent carbon. In addition, the metal that is complexed to the porphyrin ring should be cobalt, rather than carbon monoxide.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton. Phone: (703) 308-3213.

An inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.



DAVID LUKTON
PATENT EXAMINER
GROUP 1800